ClinicalTrials.gg
RecruitingNCT07231211Updated Sep 10, 2026

A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of SHR-4610 Injection and SHR-A1811 for injection in Solid Tumors, sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
258
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open, multicenter Phase I/II clinical trial, divided into two stages: dose exploration (including dose escalation and dose extension) and efficacy extension.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Shanghai Shengdi Pharmaceutical Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form;
  2. Age range: 18-75 years old, both male and female are welcome;
  3. Patients with or cytologically confirmed unresectable locally advanced or solid tumors which is to standard treatment, or lack of standard treatment;
  4. Have at least one measurable tumor lesion per v1.1;
  5. performance status of 0-1;
  6. ≥ 12 weeks;
  7. Adequate bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Patients with active central nervous system or meningeal metastases;
  2. Systemic antitumor therapy was received 4 weeks before the start of the study;
  3. Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate or higher pleural effusion or pericardial effusion;
  4. Have poorly controlled or severe cardiovascular disease;
  5. Subjects with active or active ;
  6. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per v5.0.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
258 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Group

    SHR-4610 dose A in dose escalation stage.

    Drug: SHR-4610 Injection

  • Experimental
    Cohort 2 Group

    SHR-4610 dose B in dose escalation stage.

    Drug: SHR-4610 Injection

  • Experimental
    Cohort 3 Group

    SHR-4610 dose C in dose escalation stage.

    Drug: SHR-4610 Injection

  • Experimental
    Cohort 4 Group

    SHR-4610 dose D in dose escalation stage.

    Drug: SHR-4610 Injection

  • Experimental
    Cohort 5 Group

    SHR-4610 dose A/B/C/D in dose expansion stage.

    Drug: SHR-4610 Injection

  • Experimental
    Cohort 6 Group

    SHR-4610 dose A/B/C/D in efficacy expansion stage.

    Drug: SHR-4610 Injection

  • Experimental
    Cohort 7:SHR-4610 dose D +SHR-A1811 dose A in Satefy run in Stage

    Drug: SHR-4610 Injection · Drug: SHR-A1811 for injection

  • Experimental
    Cohort 8:SHR-4610 dose D+SHR-A1811 dose A in Satefy run in Efficacy expansion stage

    Drug: SHR-4610 Injection · Drug: SHR-A1811 for injection

Interventions

06

What researchers measure

Primary outcomes

  1. The Dose-Limiting Toxicity (DLT)

    Time frame: Post-dose at day 1 to the end of treatment visit, about 1 year.

  2. The Maximum Tolerated Dose (MTD)

    Time frame: Post-dose at day 1 to the end of treatment visit, about 1 year.

  3. Recommended dosage for Phase II (RP2D)

    Time frame: Post-dose at day 1 to the end of treatment visit, about 1 year.

  4. Incidence and severity of adverse events (AEs)

    Time frame: Up to 90 days after the last administration.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Time frame: From the first administration to the end of treatment visit, about 1 year.

  2. Duration of relief (DOR)

    Time frame: From the first administration to the end of treatment visit, about 1 year.

  3. Disease Control Rate (DCR)

    Time frame: From the first administration to the end of treatment visit, about 1 year.

  4. Time to Response (TTR)

    Time frame: From the first administration to the end of treatment visit, about 1 year.

  5. Progression-free survival (PFS)

    Time frame: From the first administration to the end of treatment visit, about 1 year.

  6. Time to the maximum plasma concentration (Tmax)

    Time frame: From Day 1 pre-dose to 30 days after the last administration.

  7. Maximum concentration of SHR-4610 (Cmax)

    Time frame: From Day 1 pre-dose to 30 days after the last administration.

  8. SHR-4610 serum trough concentration (Ctrough)

    Time frame: From Day 1 pre-dose to 30 days after the last administration.

  9. Area under the concentration versus time curve of SHR-4610 from time zero to time t (AUC0-t)

    Time frame: From Day 1 pre-dose to 30 days after the last administration.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07231211
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Nov 20, 2025
Primary completion
Oct 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Yunpeng Jin
Contact
yunpeng.jin.yj1@hengrui.com
+86-021-61053363
Yuting Wang
Contact
yuting.wang@hengrui.com
+86-021-61053363

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion